Drugs / alanyl-glutamin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01955772 Background | Nov 2013 → Jul 2017 | — | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alanyl-glutamin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01955772 ↗ |
| Known as | Dipeptiven | “All patients will received, whatever treatment arm, intravenous alanyl-glutamin, Dipeptiven which have AMM.” NCT01955772 ↗ |
| Route | Intravenous | “All patients will received, whatever treatment arm, intravenous alanyl-glutamin, Dipeptiven which have AMM.” NCT01955772 ↗ |